2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
2015
A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV
Moore BA, Rosen MI, Wang Y, Shen J, Ablondi K, Sullivan A, Guerrero M, Siqueiros L, Daar ES, Liu H. A Remotely-Delivered CBT and Contingency Management Therapy for Substance Using People with HIV. AIDS And Behavior 2015, 19: 156-162. PMID: 25645326, PMCID: PMC4498993, DOI: 10.1007/s10461-014-0990-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Retroviral AgentsCaliforniaCognitive Behavioral TherapyDirective CounselingFeasibility StudiesFemaleHIV InfectionsHumansMaleMedication AdherenceMotivationPatient Acceptance of Health CareProgram EvaluationSubstance Abuse, IntravenousSubstance-Related DisordersTelephoneTreatment OutcomeYoung AdultConceptsAntiretroviral therapyContingency managementContingency management therapyBehavior therapy sessionsHIV patientsMedication adherenceTelephone sessionsPrescribed dosesParticipant adherenceManagement therapyPrior interventionsPromising interventionAlcohol useAdherenceTherapy sessionsHIVPatientsTherapyModest effectCognitive behavior therapy sessionsWeeksInterventionSessionsDosesCare
2012
Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care
Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care. Journal Of General Internal Medicine 2012, 27: 669-676. PMID: 22215271, PMCID: PMC3358393, DOI: 10.1007/s11606-011-1962-8.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineCost of IllnessCost-Benefit AnalysisDecision Support TechniquesDrug Administration ScheduleDrug CombinationsDrug CostsHealth Care CostsHumansLong-Term CareMedication AdherenceNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareQuality-Adjusted Life YearsSensitivity and SpecificityUnited StatesConceptsQuality-adjusted life yearsBUP/NXProbabilistic sensitivity analysesBup/Stable patientsOpioid dependenceLife weightsStable opioid-dependent patientsIncremental cost-effectiveness ratioOpioid-dependent patientsOpioid-dependent individualsOffice-based settingSocietal cost savingsCost-effectiveness ratioDecision analytic modelBroader health systemBuprenorphine-naloxoneOpioid useCohort studyNaloxone treatmentCare physiciansAdditional researchPrimary carePatient costsHypothetical cohort